Novavax (Gaithersburg, Md.) may not be the best-known vaccine developer, but its COVID-19 vaccine offers performance in line with those from Moderna and Pfizer. Its vaccine was 96.4% effective at preventing COVID-19 caused by the original strain of the virus in a Phase 3 study. The Moderna and Pfizer vaccines offered efficacy in the mid-90% […]
Novavax Inc.
Drug companies agree not to release COVID-19 vaccine until it’s ready
Executives from nine different drug companies today announced a pledge to ensure safety with a potential COVID-19 vaccine. The CEOs of AstraZeneca (NYSE:AZN), BioNTech (NSDQ:BNTX), GlaxoSmithKline (NYSE:GSK), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Moderna (NSDQ:MRNA), Novavax (NSDQ:NVAX), Pfizer (NYSE:PFE) and Sanofi (NYSE:SNY), all of whom are developing vaccine candidates, all signed the pledge, which vows to “uphold the integrity of the scientific process” […]
U.S. paying Novavax $1.6b to ramp up COVID-19 vaccine manufacturing
The U.S. Health and Human Services Dept. and Defense Dept. announced a joint agreement with Novavax (NSDQ:NVAX) worth $1.6 billion to scale the manufacturing of its COVID-19 vaccine candidate. Gaithersburg, Md.-based Novavax’s commercial-scale manufacturing is expected to produce 100 million doses of the investigational vaccine that would become available for use in clinical trials or, should the […]
Novavax touts nanoparticle RSV vaccine in women of child-bearing age
Novavax Inc. (NSDQ:NVAX) touted data today from the second Phase II trial of its RSV F nanoparticle vaccine candidate in women of child-bearing age. The research was published in the journal Vaccine. Novavax’s nanomedicine vaccine is being developed to protect infants from the respiratory syncytial virus. The Gaithersburg, Md.-based company presented top-line data from the Phase […]
Diamyd CEO exits over board rift | Personnel moves
Diamyd Medical AB (OTC:DMYDY) and its CEO parted ways after the chief executive had a falling out with the company’s board.
Elisabeth Lindner left her position with the company "due to disagreement with the Board concerning certain important matters," the company said in prepared remarks.
